You are here
-
Home
- Events
Biennial International LRRK2 Meeting
- Date
- 18.06.24 - 21.06.24
- Where
- Aquila Atlantis Hotel, 2 Ygias Street, Heraklion, Crete, Greece, 71 202
A conference on LRRK2 and the pathogenesis of Parkinson's diseases, from the Biochemical Society
Overview
Leucine-Rich Repeat Kinase 2 (LRRK2) is the most common genetic cause of Parkinson's disease (PD). Several penetrant mutations co-segregate with disease within multi-incident families while frequent non-coding variability in the LRRK2 locus is associated with typical late-onset, Lewy body PD. Notably, LRRK2 mutations constitutively increase its kinase activity making it a leading drug target for disease-modification in PD.
2024 marks the 20th anniversary of the cloning of the LRRK2 gene, and the field is witnessing major advances in our understanding of its function, its role in human disease and therapeutic intervention. We are pleased to welcome you to the next edition of the Biennial International LRRK2 Meeting, to be held in Crete, Greece from 18-21 June 2024, a location with rich history in medical science that is the perfect locale to showcase the very latest in research of this key protein. The conference programme will explore the genetic forms of PD, the LRRK2 gene and the LRRK2 protein as well as basic LRRK2 signaling mechanisms, and physiological and pathological functions of LRRK2. In addition, non-neuronal LRRK2 signaling, particularly with respect to neuroinflammation and the immune system in PD, will be covered as well as the role of LRRK2 in non-PD conditions and current clinical trials.
The diverse and inclusive programme will include opportunities for networking, and an emphasis will be placed on ensuring the event offers early career researchers with the vital opportunities needed to build their wider research networks with leading experts in the field. We are welcoming abstracts for both oral communications and poster presentations, from both industry and academia and across all career stages. The meeting will be of particular interest to those working in biochemistry, neuroscience, biotechnology and pharmaceuticals.
Programme Coordinators
2024 marks the 20th anniversary of the cloning of the LRRK2 gene, and the field is witnessing major advances in our understanding of its function, its role in human disease and therapeutic intervention. We are pleased to welcome you to the next edition of the Biennial International LRRK2 Meeting, to be held in Crete, Greece from 18-21 June 2024, a location with rich history in medical science that is the perfect locale to showcase the very latest in research of this key protein. The conference programme will explore the genetic forms of PD, the LRRK2 gene and the LRRK2 protein as well as basic LRRK2 signaling mechanisms, and physiological and pathological functions of LRRK2. In addition, non-neuronal LRRK2 signaling, particularly with respect to neuroinflammation and the immune system in PD, will be covered as well as the role of LRRK2 in non-PD conditions and current clinical trials.
The diverse and inclusive programme will include opportunities for networking, and an emphasis will be placed on ensuring the event offers early career researchers with the vital opportunities needed to build their wider research networks with leading experts in the field. We are welcoming abstracts for both oral communications and poster presentations, from both industry and academia and across all career stages. The meeting will be of particular interest to those working in biochemistry, neuroscience, biotechnology and pharmaceuticals.
Programme Coordinators
- Hardy Rideout, Biomedical Research Foundation of the Academy of Athens
- Esther Sammler, University of Dundee
- Sabine Hilfiker, New Jersey Medical School
- Adamantios Mamais, University of Florida